title: Comparison of long-term outcomes after allogeneic hematopoietic stem cell transplantation from matched sibling and unrelated donors.
abstract: Long-term survivors of hematopoietic stem cell transplants remain at risk of potentially fatal complications that detract from life quality. Long-term morbidity and mortality were compared between matched recipient cohorts surviving 2 or more years and defined by donor type, HLA matched sibling donor (MSD) or volunteer unrelated donor (URD). Patients were previously entered into the prospective multicenter International Unrelated Search and Transplant Study. Thirty-nine centers provided data on 108 URD and 355 MSD recipients surviving more than 2 years. Long-term survival, performance status, chronic GvHD (c-GvHD), secondary malignancy, endocrine dysfunction, cataracts, bone necrosis and dental pathology were compared between cohorts. Twelve year survival was 77+/-5% for the MSD and 67+/-11% for the URD cohort (P=0.1). Late death occurred in 105 of 463 recipients alive at 2 years, 73 after 355 (21%) MSD and 32 after 108 (30%) URD transplants, P=0.10. Of 105 deaths, the cause was relapse in 60 and unrelated to relapse in 45 cases. Cumulative incidence of extensive c-GvHD (P=0.002), cataracts (P=0.02) and bone necrosis (P=0.02) was higher after URD transplants. No long-term difference in endocrine dysfunction, secondary malignancy and major dental pathology was detected. This landmark study will assist physicians counseling patients pre-transplant and with their long-term care post transplant.
authors.affiliation: Department of Biomedical Sciences, Faculty of Applied Sciences, University of the West of England, Bristol, UK. jill.hows@bristol.ac.uk
authors.forename: J M
authors.initials: JM
authors.lastname: Hows
authors.forename: J R
authors.initials: JR
authors.lastname: Passweg
authors.forename: A
authors.initials: A
authors.lastname: Tichelli
authors.forename: A
authors.initials: A
authors.lastname: Locasciulli
authors.forename: R
authors.initials: R
authors.lastname: Szydlo
authors.forename: A
authors.initials: A
authors.lastname: Bacigalupo
authors.forename: N
authors.initials: N
authors.lastname: Jacobson
authors.forename: P
authors.initials: P
authors.lastname: Ljungman
authors.forename: J
authors.initials: J
authors.lastname: Cornish
authors.forename: A
authors.initials: A
authors.lastname: Nunn
authors.forename: B
authors.initials: B
authors.lastname: Bradley
authors.forename: G
authors.initials: G
authors.lastname: Socié
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006086:Graft vs Host Disease / Q000401:mortality* / Q000628:therapy; D019337:Hematologic Neoplasms / Q000401:mortality* / Q000628:therapy; D018380:Hematopoietic Stem Cell Transplantation / Q000401:mortality*; D006801:Humans; D007223:Infant; D008134:Long-Term Care / Q000379:methods; D008297:Male; D008875:Middle Aged; D035781:Siblings; D015996:Survival Rate; D014019:Tissue Donors